34956-06-4

Basic information

• Product Name: Carbamodithioic acid, (4-methoxyphenyl)-, methyl ester
• Synonyms: methyl 4-methoxyphenyldithiocarbamate
• CAS NO: 34956-06-4
• Molecular Formula: C9H11NOS2
• Molecular Weight: 213.324
• Mol File: 34956-06-4.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: Carbamodithioic acid, (4-methoxyphenyl)-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamodithioic acid, (4-methoxyphenyl)-, methyl ester(34956-06-4)
• EPA Substance Registry System: Carbamodithioic acid, (4-methoxyphenyl)-, methyl ester(34956-06-4)

Safety Data

• Hazardous Substances Data: 34956-06-4(Hazardous Substances Data)

Upstream product

• 75-15-0 carbon disulfide 
• 104-94-9 4-methoxy-aniline 
• 74-88-4 methyl iodide 
• 87551-36-8 sodium p-methoxyanilinedithiocarbamate 
• 123-30-8 4-amino-phenol 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 65234-02-8 3-(4-Methoxy-phenyl)-2-thioxo-2,3,5,6,7,8-hexahydro-1H-benzo[4,5]thieno[2,3-d]pyrimidin-4-one 
• 27017-09-0 6,8-dichloro-3-(4-methoxy-phenyl)-2-thioxo-2,3-dihydro-1H-quinazolin-4-one 
• 1031-88-5 3‐(4‐methoxyphenyl)‐2‐thioxo‐2,3‐dihydroquinazolin‐4(1H)‐one 
• 67811-60-3 4-(4-methoxyphenyl)-[1,2,4]triazolo[4,3-a]quinazolin-5(4H)-one 
• 66679-68-3 2-hydrazino-3-(4-methoxyphenyl)-quinazolin-4(3H)-one 
• 2293-07-4 1-(4-methoxyphenyl)thiourea 

Relevant articles and documents

Anti-HIV and Antibacterial Activities of Novel 2-(3-Substituted-4-oxo-3,4-dihydroquinazolin-2-yl)-2,3-dihydrophthalazine-1,4-diones

Abstract: In the present study, we have synthesized a series of novel 2-(3-substituted-4-oxo-3,4-dihydroquinazolin-2-yl)-2,3-dihydrophthalazine-1,4-diones by the reaction of 3-(substituted)-2-hydrazino-quinazoline-4(3H)-ones with phthalic anhydride. The starting material 3-(substituted)-2-hydrazino-quinazolin-4(3H)-ones were synthesized from various primary amines. All the synthesized compounds were screened for their antitubercular, anti-HIV and antibacterial activity against different gram positive and gram negative strains by agar dilution method. Among the test compounds, 2-(3-(4-chlorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-2,3-dihydrophthalazine-1,4-dione (QCT7) shown most potent antibacterial activity against E. coli, and S. aureus with the MIC of 3 μg/mL. The compound QCT7 exhibited the antitubercular activity with the MIC of 25 μg/mL and anti-HIV activity with the EC50 of 43.68 μM against HIV1 and HIV2 and offers potential lead for further optimization and development to new antitubercular and anti-HIV agents. The results obtained from this study confirm that the synthesized and biologically evaluated quinazolines showed promising antimicrobial, antitubercular and anti-HIV activities and are new scaffolds for antimicrobial activity.

Antimicrobial activities of some synthesized 1-(3-(2-methylphenyl)-4-Oxo-3H-quinazolin-2-yl-4-(substituted)thiosemicarbazide derivatives

The substituted thiosemicarbazide moiety was placed at the C-2 position and 2-methylphenyl group at N-3 position of quinazoline ring and obtained compounds were tested for their antitubercular activities and antibacterial activities against selected gram-positive and gram-negative bacteria. The target compounds 1-(3-(2-methylphenyl)-4-oxo-3H-quinazolin-2-yl)-4-(substituted) thiosemicarbazides were obtained by the reaction of 2-hydrazino-3-(2-methylphenyl) quinazolin-4(3H)-one with different dithiocarbamic acid methyl ester derivatives. All synthesized compounds were also screened for their antimicrobial activity against selective gram-positive and gram-negative bacteria by agar dilution method. Among the series, 1-[3-(2-methylphenyl)-4-oxo-3H-quinazolin-2-yl]-4-[4-chlorophenyl]-thiosemicarbazide exhibited the most potent activity against S. typhi, E. coli, and B. subtilis, while 1-[3-(2-methylphenyl)-4-oxo-3H-quinazolin-2-yl]-4-[4-nitrophenyl]-thiosemicarbazide was the most potent against E. coli, B. subtilis, P. aeruginosa, S. typhi, and S. flexneri. These two compounds exhibited the antitubercular activity at the minimum concentration (3 μg/mL) that offered potential for further optimization and development of new antitubercular agents. The obtained results demonstrated promising antimicrobial and antitubercular activities of the synthesized quinazoline compounds which could be used as new scaffolds for improving their antimicrobial activity.

Design, synthesis and biological evaluation of novel HSP70 inhibitors: N, N′-disubstituted thiourea derivatives

As novel heat shock protein 70 (HSP70) inhibitors, N, N′-disubstituted thiourea derivatives were designed and synthesized based on the X-ray structure of the ATPase domain (nucleotide binding domain, NBD). An ATPase activity inhibition assay revealed that these compounds effectively inhibited HSP70 ATPase activity. The results revealed that the compounds 370/371/374/379/380//392/394/397/404/405 and 407 can inhibit the HSP70 ATPase turnover with high percentages of inhibition: 50.42, 38.46, 50.45, 44.12, 47.13, 50.50, 40.95, 65.36, 46.23, 35.78, and 58.37 in 200 μM, respectively. Significant synergies with lapatinib were observed for compound 379 and compound 405 in the BT474 breast cancer cell line. A structure-function analysis revealed that most of the thiourea derivatives exhibited cooperative action with lapatinib in the BT474 cancer cell line and the BT/LapR1.0 lapatinib-resistant cell line. HSP70 inhibitors may be developed as synergetic drugs in drug-resistant cancer therapy.